To observe the oncogenic role of EGFR signaling in regulating IPO13 expression, we studied the effect of Osimertinib, a third generation of EGFR-TKI29 on IPO13 abundances in NSCLC cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.